European Journal of Inorganic Chemistry · 2016 · 31 citations · 43 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DiscoveryStructure-activity RelationshipsBioinorganic ChemistryCoordination ChemistryLigand BindingNanotoxicologyStructure-activity Relationship AnalysisComplexation ChemistryDrug-ligand ComplexationHydrolysisHydrolytic StabilityHydrophobic InteractionsHydrophobic ModificationKinetic StabilityLigand Chemistry
A new family of cytotoxic Ti IV complexes is described, based on the salalen (half salan and half salen) ligands. Altogether, 17 (salalen)Ti IV complexes with different ligand substitutions and different numbers of labile groups were synthesized. Representative complexes were characterized by X‐ray crystallography. The complexes were evaluated for their hydrolytic stability in 10 % D 2 O solutions, their cytotoxicity toward HT‐29 human colon cancer cells, and the retaining of activity after pre‐incubation in aquatic medium prior to cell addition. The results showed that: (a) reducing complexes' lability increased hydrolytic stability, (b) bulky groups often increased kinetic stability toward hydrolysis, but also damaged accessibility, (c) for unstable complexes, some hydrolysis products are likely the active species, (d) specific hydrophobic groups may facilitate penetration through the cell membrane, and (e) one di‐ tert ‐butylated salalen catecholato complex was identified as the superior derivative, combing high cytotoxicity with high stability and accessibility.
43
Noble metals in medicine: Latest advances
Serenella Medici, Massimiliano Peana, Valeria Marina Nurchi et al. · Coordination Chemistry Reviews · 2014 · 724 citations · Full text
Jeffrey H. Toney, Tobin J. Marks · Journal of the American Chemical Society · 1985 · 312 citations
Advances in Platinum Chemotherapeutics
Benjamin W. J. Harper, Anwen M. Krause‐Heuer, Maxine P. Grant et al. · Chemistry - A European Journal · 2010 · 264 citations
Pharmacy, Oncology, Pharmacology +15
Phase II trial of titanocene dichloride in advanced renal-cell carcinoma
G. Lümmen, H. Sperling, Hans Luboldt et al. · Cancer Chemotherapy and Pharmacology · 1998 · 233 citations
Medicine, Oncology, Pharmacology +8